4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were fu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2010-10, Vol.20 (20), p.6096-6099
Hauptverfasser: Liu, Kevin K.-C., Bagrodia, Shubha, Bailey, Simon, Cheng, Hengmiao, Chen, Hui, Gao, Lisa, Greasley, Samantha, Hoffman, Jacqui E., Hu, Qiyue, Johnson, Ted O., Knighton, Dan, Liu, Zhengyu, Marx, Matthew A., Nambu, Mitchell D., Ninkovic, Sacha, Pascual, Bernadette, Rafidi, Kristina, Rodgers, Caroline M.-L., Smith, Graham L., Sun, Shaoxian, Wang, Haitao, Yang, Anle, Yuan, Jing, Zou, Aihua
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3Kα and mTOR. Finally, orally active compounds with improved solubility and robust efficacy in in-vivo tumor growth inhibition were identified as well. Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3Kα and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2010.08.045